International Clinical Trial: Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (NCT07854782) titled 'Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)' on Sept. 28.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).

Primary Sponsor: Regeneron Pharmaceuticals

Condition: Metabolic Dysfunction-Associated Steatotic Liver Disease MASLD

Intervention: Drug: ALN-CIDEB

Recruitment Status: Not recruiting

Phase: Phase 3

Date of First Enrollment: November 6, 2026

Target Sample Size: 1500

To know...